Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 2:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diffuse Scleroderma Clear all
Completed Phase 1 Interventional

Mycophenolate Mofetil in Systemic Sclerosis

NCT00433186
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
Mycophenolate Mofetil
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 30, 2011 · Synced Sep 5, 2026, 2:32 PM EDT
Active, not recruiting Phase 1 Interventional

CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101

NCT06152172
View directory record Official record
Conditions
Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, SLE Nephritis, ANCA Associated Vasculitis
Interventions
KYV-101, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
David Porter
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 5, 2026, 2:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Novel Screening Strategies for Scleroderma PAH

NCT01959815
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Scleroderma
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
30 Years and older
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 14, 2021 · Synced Sep 5, 2026, 2:32 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis

NCT03313180
View directory record Official record
Conditions
Lung Diseases, Interstitial
Interventions
Nintedanib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 5, 2026, 2:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Imatinib in Systemic Sclerosis

NCT00506831
View directory record Official record
Conditions
Scleroderma, Systemic
Interventions
Imatinib mesylate
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2018 · Synced Sep 5, 2026, 2:32 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Study to Assess Sarilumab in Halting Progression of Morphea

NCT03679845
View directory record Official record
Conditions
Morphea, Plaque Form
Interventions
Sarilumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Sep 5, 2026, 2:32 PM EDT
Completed No phase listed Observational

Scleroderma Lung: Role of Gastroesophageal Reflux, Microaspiration and Cough

NCT01667042
View directory record Official record
Conditions
Scleroderma Lung
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Sep 5, 2026, 2:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Finger Hardness Measure in Scleroderma

NCT01111786
View directory record Official record
Conditions
Scleroderma
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Sep 5, 2026, 2:32 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Scleroderma: Cyclophosphamide or Transplantation

NCT00114530
View directory record Official record
Conditions
Scleroderma, Systemic, Sclerosis, Autoimmune Disease
Interventions
mHSCT, cyclophosphamide
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 69 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
15
States / cities
Duarte, California • Los Angeles, California • Lexington, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Sep 5, 2026, 2:32 PM EDT
Completed Phase 3 Interventional Results available

A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis

NCT01532869
View directory record Official record
Conditions
Sclerosis, Systemic
Interventions
Placebo, tocilizumab [RoActemra/Actemra]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
21
States / cities
Los Angeles, California • San Diego, California • Stanford, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Sep 5, 2026, 2:32 PM EDT
Recruiting Phase 4 Interventional

Open Label Treprostinil Raynaud's Study

NCT07112183
View directory record Official record
Conditions
Raynaud's Disease, Raynaud Phenomena, Raynauds
Interventions
Oral treprostinil (UT-15C) sustained release tablets
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 5, 2026, 2:32 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics of Oral Treprostinil in Patients With Systemic Sclerosis

NCT00848939
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
treprostinil diethanolamine
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 22, 2012 · Synced Sep 5, 2026, 2:32 PM EDT
Completed Phase 1 Interventional

Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma

NCT02426229
View directory record Official record
Conditions
Scleroderma, Interstitial Lung Disease
Interventions
dabigatran etexilate
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Sep 5, 2026, 2:32 PM EDT
Terminated No phase listed Observational

Duke Scleroderma Clinic Patient Registry

NCT02851875
View directory record Official record
Conditions
Scleroderma, Systemic Sclerosis
Interventions
Registry
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Sep 5, 2026, 2:32 PM EDT
Completed Phase 2 Interventional

Psychological Treatments for Scleroderma

NCT00007267
View directory record Official record
Conditions
Pain, Depression, Scleroderma, Systemic Sclerosis
Interventions
Cognitive behavioral therapy, Disease/health education, Self-help cognitive behavioral intervention facilitated by a psychologist
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 85 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Sep 5, 2026, 2:32 PM EDT
Completed Phase 2 Interventional

Trial of IC351 in Female Scleroderma Patients With Raynaud's and Sexual Dysfunction

NCT00707187
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Cialis
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 29, 2008 · Synced Sep 5, 2026, 2:32 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Cardiac Safe Transplants for Systemic Sclerosis

NCT03593902
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma
Interventions
Rituximab, Fludarabine, Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, IVIg, Autologous Stem Cells
Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Sep 5, 2026, 2:32 PM EDT
Completed No phase listed Observational

Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity

NCT03941184
View directory record Official record
Conditions
SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Celiac Disease, Crohn Disease, Dermatomyositis, Polymyositis, Guillain-Barre Syndrome, Hepatitis, Autoimmune, Graves Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Polymyalgia Rheumatica, Primary Biliary Cirrhosis, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis, Sjögren Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Type 1 Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vasculitis, Vitiligo, Raynaud
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 110 Years
Enrollment
114 participants
Timeline
1995 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Sep 5, 2026, 2:32 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Scleroderma Registry & Repository at the Hospital for Special Surgery

NCT01656447
View directory record Official record
Conditions
Scleroderma
Interventions
Not listed
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 5, 2026, 2:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Stimulatory Autoantibodies to the Platelet-Derived Growth Factor Receptor (PDGFR) in Patients With Systemic Sclerosis

NCT00667134
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Sep 5, 2026, 2:32 PM EDT
Terminated Phase 1 Interventional

Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases

NCT00849745
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Systemic Sclerosis
Interventions
Nonmyeloablative allogeneic stem cell transplant
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years to 69 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Sep 5, 2026, 2:32 PM EDT
Completed No phase listed Observational

CLUE Study: Connective Tissue Disease Leg Ulcer Etiology Study

NCT00522002
View directory record Official record
Conditions
Connective Tissue Diseases, Blood Coagulation Disorders, Leg Ulcers, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Scleroderma, Mixed Connective Tissue Disease
Interventions
Not listed
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Sep 5, 2026, 2:32 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)

NCT02453256
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Placebo, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
16
States / cities
El Cajon, California • Fullerton, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2020 · Synced Sep 5, 2026, 2:32 PM EDT
Suspended Phase 2 Interventional

Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis

NCT04166552
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
Patients will be randomized to receive EHP-101 or Placebo
Drug
Lead sponsor
Emerald Health Pharmaceuticals
Industry
Eligibility
18 Years to 74 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
13
States / cities
Phoenix, Arizona • Huntington Beach, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 5, 2026, 2:32 PM EDT